⌕
Viatris · VTRS · Nasdaq
Tenet — · insufficient data
Compare
$20.74−0.38%At close
$20.74−0.08 (−0.38%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$20.87+0.13 (+0.63%)
After hours: Nov 16, 2026, 4:44 PM ET
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Viatris (VTRS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 16, 2026 · 09:00 ET
CADILLAC FORMULA 1® TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER

Multiyear partnership brings together a U.S.-based global healthcare company and America's new Formula 1® team INDIANAPOLIS and PITTSBURGH, Nov. 16, 2026 /PRNewswire/ -- The Cadillac Formula 1® Team and Viatris Inc. (Nas…

● PRNewsWireNov 12, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year

PITTSBURGH, Nov. 12, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Fortune's World's Best Workplaces™ list for the second consecutive year, recog…

● PRNewsWireNov 11, 2026 · 06:59 ETCOMPANY'S OWN WORDS
Viatris to Participate in Upcoming Investor Conferences

PITTSBURGH, Nov. 11, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in fireside chats at three upcoming healthcare conferences. The UBS Gl…

● Zacks Investment ResearchNov 10, 2026 · 16:41 ET
VTRS or DHR: Which Is the Better Value Stock Right Now?

Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?…

● Zacks Investment ResearchNov 10, 2026 · 10:15 ET
Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue?

Viatris (VTRS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.…

● Zacks Investment ResearchNov 6, 2026 · 10:41 ET
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

● Business WireNov 5, 2026 · 17:01 ET
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. …

● Zacks Investment ResearchNov 5, 2026 · 15:30 ET
Here's What Key Metrics Tell Us About Viatris (VTRS) Q3 Earnings

The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-a…

● Seeking AlphaNov 5, 2026 · 13:34 ET
Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript

Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 5, 2026 · 11:25 ET
Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y

VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.…

● Zacks Investment ResearchNov 5, 2026 · 09:15 ET
Viatris (VTRS) Q3 Earnings Beat Estimates

Viatris (VTRS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.67 per share a year ago.…

● PRNewsWireNov 5, 2026 · 06:59 ETCOMPANY'S OWN WORDS
Viatris Reports Third-Quarter 2026 Financial Results

Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan Returns Approxima…

● Zacks Investment ResearchNov 4, 2026 · 10:16 ET
Viatris (VTRS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight…

● PRNewsWireNov 4, 2026 · 06:59 ETCOMPANY'S OWN WORDS
Viatris Announces Quarterly Dividend

PITTSBURGH, Nov. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that on November 2, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for eac…

● Zacks Investment ResearchNov 3, 2026 · 10:56 ET
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

VTRS heads into Q3 earnings with new product growth, regional sales trends and supply challenges shaping its outlook.…

● PRNewsWireOct 30, 2026 · 08:40 ETCOMPANY'S OWN WORDS
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.

PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has comme…

● Zacks Investment ResearchOct 29, 2026 · 11:01 ET
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● Zacks Investment ResearchOct 27, 2026 · 13:11 ET
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.…

● Zacks Investment ResearchOct 26, 2026 · 10:51 ET
Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

● Zacks Investment ResearchOct 20, 2026 · 10:41 ET
Here's Why Viatris (VTRS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

● PRNewsWireOct 16, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution…

● Business WireOct 12, 2026 · 12:43 ET
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. …

● Zacks Investment ResearchOct 9, 2026 · 11:40 ET
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.…

● Newsfile CorpOct 8, 2026 · 17:52 ET
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, Inc. ("Pacira BioSci…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just VTRS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.